Description of the sample
PhysIOL
IOL
A total of 60 subjects were consecutively included, 29 in the placebo group (12 men and 17 women) and 31 in the study group (10 men and 21 women). The type of IOL implanted was Finevision POD F (PhysIOL, Liège, Belgium) in 43 of the patients, and RayOne (Rayner Intraocular Lenses Ltd., Worthing, UK) in 17 of the patients. Mean age was 65.73 ± 5.74 years in the placebo group and 63.45 ± 5.78 years in the study group, with no statistically significant differences between groups (In the placebo group, mean pupillary sizes under photopic and mesopic conditions in the right eyes were 2.24 ± 0.75 mm (range, 1.00 to 3.74) and 4.63 ± 0.58 mm (range, 3.08 to 5.67), respectively, whereas in the study group, these mean values were 2.23 ± 0.71 mm (range, 0.80 to 3.70) and 4.48 ± 0.58 mm (range, 2.85 to 5.75), with no statistically significant differences between groups (No significant differences were found between placebo and study groups in terms of the IOL power implanted in the right eyes (placebo 22.8 ± 2.4 D vs. study 21.0 ± 4.1 D, Manifest refraction spherical equivalent before the visual training in the placebo group was − 0.10 ± 0.35 D (range, − 1.00 to + 1.00) in the right eyes, and 0.04 ± 0.41 D (range, − 0.75 to + 1.25) in the left eyes. In the study group, the spherical equivalent was − 0.13 ± 0.37 D (range, − 0.75 to + 0.50) in the right eyes, and − 0.04 ± 0.44 D (range, − 0.75 to + 1.25) in the left eyes. The difference between groups in the pre-training spherical equivalent of the right and left eyes did not reach statistical significance (All participants finished the training and attended all visits, although compliance with the training was not 100% in all cases. Mean compliance time was 477.67 ± 208.92 min (range, 30 to 720) and 518.16 ± 63.92 min (range, 390 to 600) in the placebo and study group, respectively. The differences between groups in this parameter were not statistically significant (